（2025年3月24日，中国上海）今日，阿斯利康宣布重度嗜酸粒细胞性哮喘（SEA）创新靶向生物制剂凡舒卓（通用名：本瑞利珠单抗注射液）在中国正式商业上市，用于成人和12岁及以上青少年重度嗜酸粒细胞性哮喘的维持治疗1。本瑞利珠单抗是精准靶向嗜酸性粒细胞 ...

Eosinophilic asthma is a more severe subtype of asthma. Treatment options include inhaled and oral corticosteroids, leukotriene modifiers, and biologics. Eosinophilic asthma is a subtype of asthma ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

A severe attack of asthma also known as “Status asthmaticus” is an asthma attack that doesn’t get better with standard treatments based on out-patient care. It makes it hard to breathe and is a ...

Interleukin 15 expression in asthmatic airways negatively correlated with lung function, a finding that improves ...

Adolescence is a vulnerable time of life, filled with emotional, physical, and social upheaval. For adolescents aged 12–19 ...

Starting in April, the biggest health insurer in Texas plans to restrict treatment options for patients suffering from severe asthma. Blue Cross Blue Shield— which covers more than 10 million Texans— ...

Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

A Northamptonshire farm contractor was rushed to Kettering Hospital after suffering a severe asthma attack triggered by ...